Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
RGEN

RGEN - Repligen Corp Stock Price, Fair Value and News

158.14USD-0.64 (-0.40%)Market Closed

Market Summary

RGEN
USD158.14-0.64
Market Closed
-0.40%

RGEN Alerts

  • 1 major insider sales recently.
  • Big fall in Revenue (Y/Y)
  • Big fall in earnings (Y/Y)

RGEN Stock Price

View Fullscreen

RGEN RSI Chart

RGEN Valuation

Market Cap

8.8B

Price/Earnings (Trailing)

595.35

Price/Sales (Trailing)

14.55

EV/EBITDA

80.58

Price/Free Cashflow

79.31

RGEN Price/Sales (Trailing)

RGEN Profitability

EBT Margin

4.96%

Return on Equity

0.75%

Return on Assets

0.52%

Free Cashflow Yield

1.26%

RGEN Fundamentals

RGEN Revenue

Revenue (TTM)

607.5M

Rev. Growth (Yr)

-17.14%

Rev. Growth (Qtr)

-2.82%

RGEN Earnings

Earnings (TTM)

14.8M

Earnings Growth (Yr)

-92.74%

Earnings Growth (Qtr)

108.22%

Breaking Down RGEN Revenue

Last 7 days

-8.0%

Last 30 days

-5.8%

Last 90 days

-19.5%

Trailing 12 Months

-5.8%

How does RGEN drawdown profile look like?

RGEN Financial Health

Current Ratio

6.35

Debt/Equity

0.26

Debt/Cashflow

0.29

RGEN Investor Care

Shares Dilution (1Y)

0.35%

Diluted EPS (TTM)

0.27

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024607.5M000
2023777.8M729.3M669.8M638.8M
2022734.1M778.8M801.3M801.5M
2021433.0M508.5M592.7M670.5M
2020285.7M302.5M327.1M366.3M
2019209.8M232.8M252.7M270.2M
2018155.5M170.8M183.7M194.0M
2017110.0M113.3M125.2M141.2M
201687.8M95.5M100.4M104.5M
201566.9M72.8M77.5M83.5M
201466.0M64.1M60.4M60.4M
201365.9M67.9M71.6M68.2M
201236.3M44.1M50.6M62.3M
201127.3M27.9M29.3M29.4M
201021.0M22.6M24.1M25.7M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Repligen Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 21, 2024
hunt anthony
sold
-3,377,280
168
-20,072
chief executive officer
May 16, 2024
pax margaret
acquired
-
-
701
-
May 16, 2024
mhatre rohin
acquired
-
-
701
-
May 16, 2024
eglinton manner carrie
acquired
-
-
701
-
May 16, 2024
madaus martin d
acquired
-
-
701
-
May 16, 2024
konstantinov konstantin
acquired
-
-
701
-
May 16, 2024
muir glenn p
acquired
-
-
701
-
May 16, 2024
dawes karen a
acquired
-
-
803
-

1–10 of 50

Which funds bought or sold RGEN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 24, 2024
Cetera Investment Advisers
added
272
706,691
958,591
-%
May 23, 2024
RAELIPSKIE PARTNERSHIP
unchanged
-
103
4,598
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
unchanged
-
151
21,151
-%
May 20, 2024
Virtu Financial LLC
added
29.29
69,000
284,000
0.02%
May 17, 2024
Aspect Partners, LLC
reduced
-12.5
-7,548
64,372
0.05%
May 16, 2024
JANE STREET GROUP, LLC
sold off
-100
-11,228,500
-
-%
May 16, 2024
B. Riley Wealth Advisors, Inc.
added
12.58
-1,049
230,533
0.01%
May 16, 2024
CASTLEARK MANAGEMENT LLC
new
-
573,830
573,830
0.02%
May 16, 2024
Tidal Investments LLC
added
11.63
32,465
261,350
-%
May 16, 2024
COMERICA BANK
reduced
-3.22
-228,465
22,626,000
0.10%

1–10 of 32

Are Funds Buying or Selling RGEN?

Are funds buying RGEN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own RGEN
No. of Funds

Unveiling Repligen Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
price t rowe associates inc /md/
7.2%
4,012,851
SC 13G/A
Feb 13, 2024
vanguard group inc
9.10%
5,078,261
SC 13G/A
Feb 06, 2024
eddleman roy t
4.85%
2,705,689
SC 13G/A
Jan 23, 2024
blackrock inc.
14.1%
7,859,530
SC 13G/A
Feb 15, 2023
eddleman roy t
4.87%
2,705,689
SC 13G/A
Feb 14, 2023
price t rowe associates inc /md/
9.1%
5,070,657
SC 13G/A
Feb 09, 2023
vanguard group inc
9.37%
5,205,155
SC 13G/A
Jan 23, 2023
blackrock inc.
11.0%
6,123,594
SC 13G/A
Sep 08, 2022
blackrock inc.
10.2%
5,686,997
SC 13G
Feb 14, 2022
price t rowe associates inc /md/
5.5%
3,042,655
SC 13G

Recent SEC filings of Repligen Corp

View All Filings
Date Filed Form Type Document
May 22, 2024
4
Insider Trading
May 21, 2024
144
Notice of Insider Sale Intent
May 20, 2024
4
Insider Trading
May 20, 2024
4
Insider Trading
May 20, 2024
4
Insider Trading
May 20, 2024
4
Insider Trading
May 20, 2024
4
Insider Trading
May 20, 2024
4
Insider Trading
May 20, 2024
4
Insider Trading
May 20, 2024
4
Insider Trading

Peers (Alternatives to Repligen Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
180.8B
40.3B
-2.76% 1.76%
32.15
4.48
-2.84% -3.08%
66.1B
19.7B
-2.16% -5.37%
49.6
3.35
4.82% -17.56%
19.2B
3.9B
-18.57% -8.78%
41.61
4.91
5.72% 46.72%
17.3B
14.9B
-17.18% -18.00%
6.52
1.16
2.98% 207.68%
MID-CAP
9.8B
3.5B
5.71% 30.36%
31.35
2.77
6.16% 35.06%
9.2B
12.5B
-2.02% -4.46%
23.67
0.74
-0.61% -18.83%
8.2B
2.6B
3.21% -23.01%
-25.4
3.14
-6.25% -68.62%
5.7B
3.9B
-11.19% -25.60%
-60.98
1.45
0.23% 91.03%
3.4B
387.1M
0.92% 35.45%
-215.34
8.86
30.82% 65.57%
2.1B
6.6B
-8.59% -8.66%
11.08
0.33
2.78% -0.87%
SMALL-CAP
1.3B
3.2B
3.07% -4.64%
-1.93
0.41
7.94% -1661.78%
363.3M
169.3M
-5.41% -8.85%
-4.73
2.15
7.49% -244.90%
247.5M
324.0M
5.28% -34.04%
-1.29
0.76
-3.19% -337.41%
55.4M
50.5M
6.67% -73.38%
-2.43
1.1
14.25% -10.06%
1.1M
3.7M
-72.55% -86.00%
-0.09
0.29
5.77% 8.23%

Repligen Corp News

Latest updates
Yahoo Lifestyle Australia33 hours ago
MarketBeat21 May 202410:40 am

Repligen Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-2.8%15115614115918318720120820618717816314310994.0087.0076.0069.0069.0071.0061.00
Gross Profit--------------60.0054.0051.0044.0039.0038.0040.0034.00
Costs and Expenses-4.7%14915713614015113814814414614913311510691.0073.0068.0064.0064.0061.0060.0049.00
Operating Expenses--------------91.0073.0068.0064.0064.0061.0060.0049.00
  S&GA Expenses7.3%62.0058.0055.0049.0056.0053.0054.0055.0054.0052.0048.0044.0039.0036.0029.0027.0028.0028.0025.0024.0019.00
  R&D Expenses9.3%11.0010.0011.0010.0012.0011.0010.0010.0012.009.009.008.008.007.004.004.005.005.005.005.004.00
EBITDA Margin-16.6%0.18*0.21*0.29*0.30*0.32*0.34*0.31*0.32*0.31*0.30*0.30*0.30*---------
Interest Expenses329.8%5.001.000.000.000.000.000.000.000.003.003.003.003.002.003.003.003.003.003.002.002.00
Income Taxes-99.9%0.0017.00-6.535.007.004.007.0010.0012.006.008.008.004.00-4.923.000.001.001.000.002.002.00
Earnings Before Taxes124.1%2.00-8.7612.0025.0036.0053.0047.0060.0059.0035.0041.0044.0033.0015.0018.0016.0011.004.002.0010.0011.00
EBT Margin-50.6%0.05*0.10*0.19*0.22*0.25*0.27*0.25*0.25*0.24*0.23*0.23*0.22*---------
Net Income108.2%2.00-25.4918.0020.0029.0049.0040.0050.0047.0029.0033.0036.0029.0020.0015.0016.0010.004.002.008.008.00
Net Income Margin-62.5%0.02*0.07*0.17*0.19*0.22*0.23*0.21*0.20*0.20*0.19*0.20*0.20*---------
Free Cashflow102.3%36.0018.0031.0026.003.0041.0030.0020.00-4.0918.0012.0021.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets0.9%2,8492,8242,5142,5492,5382,5252,4632,4452,3842,3582,2412,0161,9271,9031,4761,4421,4061,4001,3791,068798
  Current Assets2.0%1,1331,1119789991,019998953976945932911984926902697687651642622316284
    Cash Equivalents3.9%781751631604517523573597585604621734711717553560539537522218196
  Inventory-2.1%19820221124124523824323921418415613611095.0079.0070.0062.0055.0052.0051.0045.00
  Net PPE-0.8%20620720220319319117416814812510085.0072.0067.0055.0052.0050.0048.0043.0038.0035.00
  Goodwill-0.1%98698786987185685685185485986083461861861848213.00468468469470326
Liabilities3.0%879853526578598614627640617608526413371374351342337340334189173
  Current Liabilities12.7%17815836337440540441142442437534933231331951.0044.0042.0048.0039.00141130
  Long Term Debt0.7%514510-------------------
    LT Debt, Non Current-100.0%-510-------------------
Shareholder's Equity0.0%1,9711,9711,9891,9711,9401,9111,8351,8051,7661,7501,7151,6031,5561,5291,1251,1001,0701,0601,045879625
  Retained Earnings0.5%44143946444642639734930825819416513195.0066.0046.0032.0016.006.002.001.00-7.51
  Additional Paid-In Capital0.2%1,5721,5691,5671,5611,5451,5471,5411,5341,5291,5721,5601,4751,4681,4611,0881,0821,0741,0681,064893646
Accumulated Depreciation5.5%136129-------------------
Shares Outstanding0.1%56.0056.0056.0056.0056.0056.0056.0055.0055.0055.0055.0055.00---------
Float----6,932---8,912---10,858---5,712---3,600-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations53.8%44,70829,06539,23134,46811,15461,88241,36745,72123,11349,62022,48337,6519,26214,87121,48916,7359,53017,67421,96517,7899,788
  Share Based Compensation35.7%8,7766,4656,3735,4837,2546,2626,1546,9857,9157,0206,8007,1436,5414,5154,2254,1024,1653,3773,2003,0313,251
Cashflow From Investing95.1%-8,362-169,905-8,77064,833-9,433-121,308-57,494-26,220-28,214-62,276-132,695-17,201-8,997-158,288-33,580-4,480-5,037-7,111-6,892-187,477-3,828
Cashflow From Financing-103.3%-8,974268,127-778-8,825-9,563-2741,251-2,293-12,021231-122345507298,8381,6763,8131,589-180294,875190,12844.00
  Buy Backs-----------330-----------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

RGEN Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:  
Revenue$ 151,346$ 182,660
Costs and operating expenses:  
Cost of goods sold76,39181,845
Research and development11,23812,154
Selling, general and administrative61,68656,170
Contingent consideration01,235
Total costs and operating expenses149,315151,404
Income from operations2,03131,256
Other income (expenses):  
Investment income8,9935,486
Interest expense(4,891)(270)
Amortization of debt issuance costs(483)(457)
Other (expenses) income(3,536)77
Other income, net834,836
Income before income taxes2,11436,092
Income tax provision207,263
Net income$ 2,094$ 28,829
Earnings per share:  
Basic$ 0.04$ 0.52
Diluted$ 0.04$ 0.51
Weighted average common shares outstanding:  
Basic55,79155,590
Diluted56,53157,049
Net Income (Loss)$ 2,094$ 28,829
Other comprehensive income (loss):  
Foreign currency translation adjustment(5,281)3,273
Comprehensive (loss) income(3,187)32,102
Products  
Revenue:  
Revenue151,310182,621
Royalty and other revenue  
Revenue:  
Revenue$ 36$ 39

RGEN Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 780,617$ 751,323
Accounts receivable, net of reserves of $1,918 and $2,122 at March 31, 2024 and December 31, 2023, respectively115,766124,161
Inventories, net198,033202,321
Assets held for sale1,0160
Prepaid expenses and other current assets37,58633,238
Total current assets1,133,0181,111,043
Property, plant and equipment, net205,716207,440
Intangible assets, net388,146400,486
Goodwill985,963987,120
Deferred tax assets8661,530
Operating lease right of use assets134,604115,515
Other noncurrent assets9561,277
Total noncurrent assets1,716,2511,713,368
Total assets2,849,2692,824,411
Current liabilities:  
Accounts payable18,73119,563
Operating lease liability9,7815,631
Current contingent consideration24,35212,983
Accrued liabilities55,97150,533
Convertible Senior Notes due 2024, net69,48069,452
Total current liabilities178,315158,162
Convertible Senior Notes due 2028, net513,918510,143
Deferred tax liabilities38,23840,466
Noncurrent operating lease liability144,551126,578
Noncurrent contingent consideration014,070
Other noncurrent liabilities3,6463,789
Total noncurrent liabilities700,353695,046
Total liabilities878,668853,208
Commitments and contingencies (Note 10)
Stockholders' equity:  
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding00
Common stock, $0.01 par value; 80,000,000 shares authorized; 55,841,318 shares at March 31, 2024 and 55,766,078 shares at December 31, 2023 issued and outstanding559558
Additional paid-in capital1,571,8111,569,227
Accumulated other comprehensive loss(42,712)(37,431)
Accumulated earnings440,943438,849
Total stockholders' equity1,970,6011,971,203
Total liabilities and stockholders' equity$ 2,849,269$ 2,824,411
RGEN
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
 CEO
 WEBSITErepligen.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES2025

Repligen Corp Frequently Asked Questions


What is the ticker symbol for Repligen Corp? What does RGEN stand for in stocks?

RGEN is the stock ticker symbol of Repligen Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Repligen Corp (RGEN)?

As of Fri May 24 2024, market cap of Repligen Corp is 8.84 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RGEN stock?

You can check RGEN's fair value in chart for subscribers.

What is the fair value of RGEN stock?

You can check RGEN's fair value in chart for subscribers. The fair value of Repligen Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Repligen Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RGEN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Repligen Corp a good stock to buy?

The fair value guage provides a quick view whether RGEN is over valued or under valued. Whether Repligen Corp is cheap or expensive depends on the assumptions which impact Repligen Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RGEN.

What is Repligen Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 24 2024, RGEN's PE ratio (Price to Earnings) is 595.35 and Price to Sales (PS) ratio is 14.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RGEN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Repligen Corp's stock?

In the past 10 years, Repligen Corp has provided 0.236 (multiply by 100 for percentage) rate of return.